Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

October 21, 2021

Study Completion Date

October 21, 2021

Conditions
Glycogen Storage Disease Type I
Interventions
DRUG

Triheptanoin

This is an open-label study. The UX007 (triheptanoin) starting dose will be 0.25 - 0.5 g/kg and titrated to a maximum of 2.5g/kg depending the on the subject's tolerance. The dose may be reduced if not tolerated. The compound will be administered 3-4 times per day, either at the end of a meal or with a snack. It should be given at least 2 hours apart from any cornstarch dose to allow each to act independent of one another, and to prevent the risk of increased gastrointestinal side effects. The doses may be held during episodes of gastroenteritis or diarrhea.

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

Ultragenyx Pharmaceutical Inc

INDUSTRY

lead

Areeg El-Gharbawy

OTHER

NCT03665636 - Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I | Biotech Hunter | Biotech Hunter